Savient's Krystexxa Wins Advisory Cmte. Endorsement
In light of a cardiovascular signal but insufficient data, panel recommends a REMS with provider registration for the orphan biologic.
In light of a cardiovascular signal but insufficient data, panel recommends a REMS with provider registration for the orphan biologic.